Patricia Taik

Patricia Taik

Auto-generated profile, based on publicly available information

Patricia Taik

Sema4, Stamford, Connecticut

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
RPRoser Pinyol
Roser Pinyol
STSara Torrecilla
Sara Torrecilla
HWHuan Wang
Huan Wang
CMCarla Montironi
Carla Montironi
MPMarta Piqué-Gili
Marta Piqué-Gili
JLJosep M. Llovet
Josep M. Llovet

3 May 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
EBErdem Bangi
Erdem Bangi
CACelina Ang
Celina Ang
PSPeter Smibert
Peter Smibert
AUAndrew V. Uzilov
Andrew V. Uzilov
ATAlexander G. Teague
Alexander G. Teague
RCRoss L. Cagan
Ross L. Cagan
A novel Drosophila -based approach resulted in a significant response by a patient with KRAS-mutant colorectal cancer.

21 November 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AUAndrew V Uzilov
Andrew V Uzilov
PTPatricia Taik
Patricia Taik
KCKhadeen C Cheesman
Khadeen C Cheesman
PJPedram Javanmard
Pedram Javanmard
KYKai Ying
Kai Ying
EGEliza B Geer
Eliza B Geer
Context: Pituitary corticotroph adenomas are rare tumors that can be associated with excess adrenocorticotropin (ACTH) and adrenal cortisol production, resulting in the clinically debilitating endocrine condition Cushing disease. A subset of corticotroph tumors behave aggressively, and genomic drivers behind the development of these tumors are largely unknown. Objective: To investigate genomic drivers of corticotroph tumors at risk for aggressive behavior. Design: Whole-exome sequencing of patient-matched corticotroph tumor and normal deoxyribonucleic acid (DNA) from a patient cohort enriched for tumors at risk for aggressive behavior. Setting: Tertiary care center Patients: Twenty-seven corticotroph tumors from 22 patients were analyzed. Twelve tumors were macroadenomas, of which 6 were silent ACTH tumors, 2 were Crooke’s cell tumors, and 1 was a corticotroph carcinoma. Intervention: Whole-exome sequencing. Main outcome measure: Somatic mutation genomic biomarkers. Results: We found recurrent somatic mutations in USP8 and TP53 genes, both with higher allelic fractions than other somatic mutations. These mutations were mutually exclusive, with TP53 mutations occurring only in USP8 wildtype (WT) tumors, indicating they may be independent driver genes. USP8-WT tumors were characterized by extensive somatic copy number variation compared with USP8-mutated tumors. Independent of molecular driver status, we found an association between invasiveness, macroadenomas, and aneuploidy. Conclusions: Our data suggest that corticotroph tumors may be categorized into a USP8-mutated, genome-stable subtype versus a USP8-WT, genome-disrupted subtype, the latter of which has a TP53-mutated subtype with high level of chromosome instability. These findings could help identify high risk corticotroph tumors, namely those with widespread CNV, that may need closer monitoring and more aggressive treatment.

1 March 2021 in iScience
Verified
Journal Article
Open access
EBErdem Bangi
Erdem Bangi
PSPeter Smibert
Peter Smibert
AUAndrew V. Uzilov
Andrew V. Uzilov
ATAlexander G. Teague
Alexander G. Teague
SGSindhura Gopinath
Sindhura Gopinath
RCRoss L. Cagan
Ross L. Cagan
Adenoid cystic carcinoma (ACC) is a rare cancer type that originates in the salivary glands. Tumors commonly invade along nerve tracks in the head and neck, making surgery challenging. Follow-up treatments for recurrence or metastasis including chemotherapy and targeted therapies have shown limited efficacy, emphasizing the need for new therapies. Here, we report a Drosophila-based therapeutic approach for a patient with advanced ACC disease. A patient-specific Drosophila transgenic line was developed to model the five major variants associated with the patient's disease. Robotics-based screening identified a three-drug cocktail—vorinostat, pindolol, tofacitinib—that rescued transgene-mediated lethality in the Drosophila patient-specific line. Patient treatment led to a sustained stabilization and a partial metabolic response of 12 months. Subsequent resistance was associated with new genomic amplifications and deletions. Given the lack of options for patients with ACC, our data suggest that this approach may prove useful for identifying novel therapeutic candidates.

23 August 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LTLaura Torrens
Laura Torrens
MPMarc Puigvehí
Marc Puigvehí
MTMiguel Torres-Martín
Miguel Torres-Martín
HWHuan Wang
Huan Wang
MMMiho Maeda
Miho Maeda
JLJosep M. Llovet
Josep M. Llovet
Purpose: Mongolia has the world's highest incidence of hepatocellular carcinoma (HCC), with ∼100 cases/100,000 inhabitants, although the reasons for this have not been thoroughly delineated. Experimental Design: We performed a molecular characterization of Mongolian (n = 192) compared with Western (n = 187) HCCs by RNA sequencing and whole-exome sequencing to unveil distinct genomic and transcriptomic features associated with environmental factors in this population. Results: Mongolian patients were younger, with higher female prevalence, and with predominantly HBV–HDV coinfection etiology. Mongolian HCCs presented significantly higher rates of protein-coding mutations (121 vs. 70 mutations per tumor in Western), and in specific driver HCC genes (i.e., APOB and TSC2). Four mutational signatures characterized Mongolian samples, one of which was novel (SBS Mongolia) and present in 25% of Mongolian HCC cases. This signature showed a distinct substitution profile with a high proportion of T>G substitutions and was significantly associated with a signature of exposure to the environmental agent dimethyl sulfate (71%), a 2A carcinogenic associated with coal combustion. Transcriptomic-based analysis delineated three molecular clusters, two not present in Western HCC; one with a highly inflamed profile and the other significantly associated with younger female patients. Conclusions: Mongolian HCC has unique molecular traits with a high mutational burden and a novel mutational signature associated with genotoxic environmental factors present in this country.

1 July 2017 in Molecular Phylogenetics and Evolution
Verified
Journal Article
Closed access
HCHongshu Chi
Hongshu Chi
PTPatricia Taik
Patricia Taik
EFEmily J. Foley
Emily J. Foley
ARAlycia C. Racicot
Alycia C. Racicot
HGHilary M. Gray
Hilary M. Gray
HGHui Gong
Hui Gong